GENinCode’s £17 Million Initial Public Offering

Addleshaw Goddard advised GENinCode.
Specialising in cardiovascular disease risk assessment, GENinCode’s products combine genetic and clinical data to risk assess patients and provide doctors with advanced clinical information and genetic insight to predict the onset of cardiovascular disease, enabling them to determine the most effective treatment plans for patients, including making lifestyle changes, which can help prevent the onset of cardiovascular disease.
The AIM listing sees the company valued at £42.2 million, raising £17m by way of a Placing. This will be used to assist GENinCode as it focuses on achieving US regulatory approval and commercialising its products in the US, further expansion into the EU, and expanding into the UK market.
Directors at GENinCode are confident that the listing will enhance the Company’s profile and increase awareness of its products, enabling it to be at the forefront of the application of genetics to update the current standard of care for the assessment and prevention of cardiovascular disease, the number one cause of death throughout the world.
Led by corporate partner Anna Brown (Picture), the Addleshaw Goddard team which supported GENinCode included partner, Murray Jack, associate, Michael Flett, associate, Mhairi Cruikshank, trainee solicitor, Finlay MacDougall, and trainee solicitor, Ashley Thomson. 
Involved fees earner: Anna Brown – Addleshaw Goddard; Mhairi Cruikshank – Addleshaw Goddard; Michael Flett – Addleshaw Goddard; Murray Jack – Addleshaw Goddard; Law Firms: Addleshaw Goddard; Clients: GENinCode;

Author: Giulia Di Palma